Real-world data assessment of safety of home-based and hospital/outpatient-based laronidase enzyme replacement therapy for mucopolysaccharidosis I

類似資料

• Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I
  著者:: Jameson, Elisabeth, 等
  出版事項: (2019)
• Laronidase Replacement Therapy and Left Ventricular Function in Mucopolysaccharidosis I
  著者:: Harada, Haruhito, 等
  出版事項: (2014)
• Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease
  著者:: Hsu, Yu-Hone, 等
  出版事項: (2017)
• Efficacy and safety of a biosimilar laronidase versus the reference laronidase in patients with mucopolysaccharidosis type I
  著者:: Ali Rabbani, 等
  出版事項: (2025-08-01)
• Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
  著者:: Zhuomiao Lin, 等
  出版事項: (2025-08-01)